| pubmed-article:12937844 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12937844 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:12937844 | lifeskim:mentions | umls-concept:C0021084 | lld:lifeskim |
| pubmed-article:12937844 | lifeskim:mentions | umls-concept:C0333668 | lld:lifeskim |
| pubmed-article:12937844 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:12937844 | pubmed:dateCreated | 2003-8-25 | lld:pubmed |
| pubmed-article:12937844 | pubmed:abstractText | Allogeneic hematopoietic stem cell transplantation is the treatment of choice for many hematological malignancies. Its efficacy is limited by graft-versus-host disease (GVHD), the leading cause of post-transplant morbidity and mortality. GVHD is mediated by a subpopulation of T cells in the stem cell graft. Ex vivo T cell depletion of all T cells of the graft can prevent development of GVHD but can lead to a delay in immune reconstitution and an increase of potentially lethal opportunistic infections and leukemic relapses. Hypothetically, an approach that enables a selective depletion of the alloreactive donor T cells that cause GVHD while preserving third party (anti-leukemic and anti-microbial) reactivity would be optimal for recipients of HSCT. Our preliminary data demonstrated that an anti-CD25 immunotoxin, which reacts with a cell surface activation antigen, can selectively deplete alloreactive donor T cells activated by non-leukemic recipient white blood cells while preserving the beneficial third-party reactivity in vitro. In this report we describe a method for clinical-scale ex vivo selective depletion of alloreactive donor T cells using the anti-CD25 immunotoxin, RFT5-SMPT-dgRTA. Two logs of alloreactive T cells could be selectively depleted while preserving third party reactivity. This method was reproducible in 10 pre-clinical experiments with 8 HLA-mismatched healthy volunteer pairs and 2 HLA-matched sibling donor/patient pairs. | lld:pubmed |
| pubmed-article:12937844 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12937844 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12937844 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12937844 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12937844 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12937844 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12937844 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12937844 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12937844 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12937844 | pubmed:issn | 0028-2685 | lld:pubmed |
| pubmed-article:12937844 | pubmed:author | pubmed-author:VitettaE SES | lld:pubmed |
| pubmed-article:12937844 | pubmed:author | pubmed-author:MichálekJJ | lld:pubmed |
| pubmed-article:12937844 | pubmed:author | pubmed-author:CollinsR HRH | lld:pubmed |
| pubmed-article:12937844 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12937844 | pubmed:volume | 50 | lld:pubmed |
| pubmed-article:12937844 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12937844 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12937844 | pubmed:pagination | 296-9 | lld:pubmed |
| pubmed-article:12937844 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:12937844 | pubmed:meshHeading | pubmed-meshheading:12937844... | lld:pubmed |
| pubmed-article:12937844 | pubmed:meshHeading | pubmed-meshheading:12937844... | lld:pubmed |
| pubmed-article:12937844 | pubmed:meshHeading | pubmed-meshheading:12937844... | lld:pubmed |
| pubmed-article:12937844 | pubmed:meshHeading | pubmed-meshheading:12937844... | lld:pubmed |
| pubmed-article:12937844 | pubmed:meshHeading | pubmed-meshheading:12937844... | lld:pubmed |
| pubmed-article:12937844 | pubmed:meshHeading | pubmed-meshheading:12937844... | lld:pubmed |
| pubmed-article:12937844 | pubmed:meshHeading | pubmed-meshheading:12937844... | lld:pubmed |
| pubmed-article:12937844 | pubmed:meshHeading | pubmed-meshheading:12937844... | lld:pubmed |
| pubmed-article:12937844 | pubmed:meshHeading | pubmed-meshheading:12937844... | lld:pubmed |
| pubmed-article:12937844 | pubmed:meshHeading | pubmed-meshheading:12937844... | lld:pubmed |
| pubmed-article:12937844 | pubmed:meshHeading | pubmed-meshheading:12937844... | lld:pubmed |
| pubmed-article:12937844 | pubmed:meshHeading | pubmed-meshheading:12937844... | lld:pubmed |
| pubmed-article:12937844 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12937844 | pubmed:articleTitle | Clinical-scale selective depletion of alloreactive T cells using an anti-CD25 immunotoxin. | lld:pubmed |
| pubmed-article:12937844 | pubmed:affiliation | Cancer Immunobiology Center, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390 USA. jmichal@med.muni.cz | lld:pubmed |
| pubmed-article:12937844 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12937844 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12937844 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12937844 | lld:pubmed |
